719 related articles for article (PubMed ID: 28122895)
1. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
Mamounas EP; Liu Q; Paik S; Baehner FL; Tang G; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Wickerham DL; Costantino JP; Wolmark N
J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122895
[TBL] [Abstract][Full Text] [Related]
2. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
[TBL] [Abstract][Full Text] [Related]
3. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
Woodward WA; Barlow WE; Jagsi R; Buchholz TA; Shak S; Baehner F; Whelan TJ; Davidson NE; Ingle JN; King TA; Ravdin PM; Osborne CK; Tripathy D; Livingston RB; Gralow JR; Hortobagyi GN; Hayes DF; Albain KS
JAMA Oncol; 2020 Apr; 6(4):505-511. PubMed ID: 31917424
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
5. 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.
Turashvili G; Chou JF; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
Breast Cancer Res Treat; 2017 Nov; 166(1):69-76. PubMed ID: 28702894
[TBL] [Abstract][Full Text] [Related]
6. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
7. Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
Turashvili G; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
BMC Cancer; 2018 Jan; 18(1):42. PubMed ID: 29304773
[TBL] [Abstract][Full Text] [Related]
8. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Mamounas EP; Tang G; Fisher B; Paik S; Shak S; Costantino JP; Watson D; Geyer CE; Wickerham DL; Wolmark N
J Clin Oncol; 2010 Apr; 28(10):1677-83. PubMed ID: 20065188
[TBL] [Abstract][Full Text] [Related]
9. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
Mamounas EP; Anderson SJ; Dignam JJ; Bear HD; Julian TB; Geyer CE; Taghian A; Wickerham DL; Wolmark N
J Clin Oncol; 2012 Nov; 30(32):3960-6. PubMed ID: 23032615
[TBL] [Abstract][Full Text] [Related]
10. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
[TBL] [Abstract][Full Text] [Related]
11. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
12. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
[TBL] [Abstract][Full Text] [Related]
13. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
Garg AK; Strom EA; McNeese MD; Buzdar AU; Hortobagyi GN; Kuerer HM; Perkins GH; Singletary SE; Hunt KK; Sahin A; Schechter N; Valero V; Tucker SL; Buchholz TA
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):138-45. PubMed ID: 15093909
[TBL] [Abstract][Full Text] [Related]
14. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344.
Sartor CI; Peterson BL; Woolf S; Fitzgerald TJ; Laurie F; Turrisi AJ; Bogart J; Henderson IC; Norton L
J Clin Oncol; 2005 Jan; 23(1):30-40. PubMed ID: 15545661
[TBL] [Abstract][Full Text] [Related]
15. Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
van Hezewijk M; Bastiaannet E; Putter H; Scholten AN; Liefers GJ; Rea D; Hasenburg A; Paridaens R; Hozumi Y; Markopoulos C; Seynaeve C; Jones SE; Marijnen CA; van de Velde CJ
Radiother Oncol; 2013 Aug; 108(2):190-6. PubMed ID: 24044798
[TBL] [Abstract][Full Text] [Related]
16. [Impact of the 21-gene recurrence score assay in clinical treatment and prognosis analysis for patients with hormone receptor positive early-stage breast cancer].
Zhang YN; Zhou YD; Mao F; Guan JH; Lin Y; Wang XJ; Shen SJ; Wang CJ; Yao R; Sun Q
Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):110-114. PubMed ID: 29502370
[No Abstract] [Full Text] [Related]
17. Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy.
Cheng JC; Chen CM; Liu MC; Tsou MH; Yang PS; Jian JJ; Cheng SH; Tsai SY; Leu SY; Huang AT
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):980-8. PubMed ID: 11958892
[TBL] [Abstract][Full Text] [Related]
18. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status.
Yang PS; Chen CM; Liu MC; Jian JM; Horng CF; Liu MJ; Yu BL; Lee MY; Chi CW
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):516-22. PubMed ID: 19577858
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
